US20040092818A1 - Radiopaque surgical implement - Google Patents
Radiopaque surgical implement Download PDFInfo
- Publication number
- US20040092818A1 US20040092818A1 US10/701,223 US70122303A US2004092818A1 US 20040092818 A1 US20040092818 A1 US 20040092818A1 US 70122303 A US70122303 A US 70122303A US 2004092818 A1 US2004092818 A1 US 2004092818A1
- Authority
- US
- United States
- Prior art keywords
- radiopaque
- radiolucent
- materials
- group
- carbide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000463 material Substances 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 239000011230 binding agent Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000005245 sintering Methods 0.000 claims abstract description 16
- 229910010293 ceramic material Inorganic materials 0.000 claims abstract description 12
- 239000011236 particulate material Substances 0.000 claims abstract description 11
- 238000001746 injection moulding Methods 0.000 claims abstract description 5
- 229910052751 metal Inorganic materials 0.000 claims description 20
- 239000002184 metal Substances 0.000 claims description 20
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 18
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 229910001220 stainless steel Inorganic materials 0.000 claims description 14
- 239000010935 stainless steel Substances 0.000 claims description 13
- 150000002739 metals Chemical class 0.000 claims description 12
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 11
- 229910052721 tungsten Inorganic materials 0.000 claims description 11
- 239000010937 tungsten Substances 0.000 claims description 11
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 10
- 229910052697 platinum Inorganic materials 0.000 claims description 9
- 229910052715 tantalum Inorganic materials 0.000 claims description 9
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052702 rhenium Inorganic materials 0.000 claims description 8
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- -1 sialon Chemical compound 0.000 claims description 6
- 229910045601 alloy Inorganic materials 0.000 claims description 5
- 239000000956 alloy Substances 0.000 claims description 5
- 229910044991 metal oxide Inorganic materials 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 238000012800 visualization Methods 0.000 claims description 5
- OFEAOSSMQHGXMM-UHFFFAOYSA-N 12007-10-2 Chemical compound [W].[W]=[B] OFEAOSSMQHGXMM-UHFFFAOYSA-N 0.000 claims description 4
- QYEXBYZXHDUPRC-UHFFFAOYSA-N B#[Ti]#B Chemical compound B#[Ti]#B QYEXBYZXHDUPRC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052580 B4C Inorganic materials 0.000 claims description 4
- 229910052582 BN Inorganic materials 0.000 claims description 4
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 claims description 4
- 229910052581 Si3N4 Inorganic materials 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 4
- 229910026551 ZrC Inorganic materials 0.000 claims description 4
- OTCHGXYCWNXDOA-UHFFFAOYSA-N [C].[Zr] Chemical compound [C].[Zr] OTCHGXYCWNXDOA-UHFFFAOYSA-N 0.000 claims description 4
- 229910002113 barium titanate Inorganic materials 0.000 claims description 4
- JRPBQTZRNDNNOP-UHFFFAOYSA-N barium titanate Chemical compound [Ba+2].[Ba+2].[O-][Ti]([O-])([O-])[O-] JRPBQTZRNDNNOP-UHFFFAOYSA-N 0.000 claims description 4
- INAHAJYZKVIDIZ-UHFFFAOYSA-N boron carbide Chemical compound B12B3B4C32B41 INAHAJYZKVIDIZ-UHFFFAOYSA-N 0.000 claims description 4
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000292 calcium oxide Substances 0.000 claims description 4
- PMHQVHHXPFUNSP-UHFFFAOYSA-M copper(1+);methylsulfanylmethane;bromide Chemical compound Br[Cu].CSC PMHQVHHXPFUNSP-UHFFFAOYSA-M 0.000 claims description 4
- 238000002594 fluoroscopy Methods 0.000 claims description 4
- 229910052741 iridium Inorganic materials 0.000 claims description 4
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052759 nickel Inorganic materials 0.000 claims description 4
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 4
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 229910010271 silicon carbide Inorganic materials 0.000 claims description 4
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 239000010936 titanium Substances 0.000 claims description 4
- MTPVUVINMAGMJL-UHFFFAOYSA-N trimethyl(1,1,2,2,2-pentafluoroethyl)silane Chemical compound C[Si](C)(C)C(F)(F)C(F)(F)F MTPVUVINMAGMJL-UHFFFAOYSA-N 0.000 claims description 4
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052726 zirconium Inorganic materials 0.000 claims description 4
- ZVWKZXLXHLZXLS-UHFFFAOYSA-N zirconium nitride Chemical compound [Zr]#N ZVWKZXLXHLZXLS-UHFFFAOYSA-N 0.000 claims description 4
- 229920006324 polyoxymethylene Polymers 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 3
- 229910052737 gold Inorganic materials 0.000 claims 3
- 239000010931 gold Substances 0.000 claims 3
- 230000008569 process Effects 0.000 abstract description 8
- 238000012978 minimally invasive surgical procedure Methods 0.000 abstract description 2
- 239000000919 ceramic Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 238000003754 machining Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- GZRDJPGWGMWUQZ-UHFFFAOYSA-N [Re].[Au] Chemical compound [Re].[Au] GZRDJPGWGMWUQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011195 cermet Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000007733 ion plating Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000012255 powdered metal Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
Definitions
- This invention relates to medical devices which are inserted into the body and located by X-ray imaging.
- catheters or similar devices are used to convey a operative implement through a body passage, including such passages as the blood vessels, gastrointestinal tract, urethral and urethral tracts, bronchial and esophageal tracts, to a specific location where the implement is operatively employed or delivered.
- Catheters are used to perform balloon angioplasty, to deliver and lodge stent devices, to deliver drugs, to abrade or volatilize lesions, to remove temporary, misplaced or dislodged stents, and the like.
- X-ray imaging is often used to follow the catheter or the operative implement as it traverses the body channel and/or to monitor the actual employment or deployment of the implement.
- a number of the implements, used or delivered by such techniques, or parts thereof may be made of metal or ceramic materials. Traditionally such implements are, or are made up of, small complex machined parts. Stents are an example of such an implement which is typically made by machining metal.
- a technique which is known for manufacturing metal and ceramic parts utilizes injection molding and sintering of composite formulations.
- This technique designated “CIM” for ceramic articles and “MIM” for metal articles utilizes formulations which are mixtures of a resinous binder material and a very fine powder of the respective ceramic or metal material, which is injection molded to produce a desired shaped article, the molded article typically being somewhat larger than the desired size.
- the binder is then typically removed by extraction, heating, or both, leaving a shaped structure of the powder material. This structure is sintered to form the final article, typically shrinking by a reproducible amount.
- a porous stent formed by a powdered metal sintering process is disclosed in U.S. Pat. No. 5,972,027, incorporated herein by reference in its entirety.
- a perfulsion tip for an ablation catheter is described in U.S. 6,017,338, incorporated herein by reference in its entirety.
- the present invention is directed to articles which can be made using a CIM or MIM process, preferably articles which are, or are part, of surgical implement structures such as catheters, forcepts, stents, perfusion heads, electrodes, and the like used in minimally invasive surgical procedures and.
- the invention also relates to CIM or MIM processes for preparing such implements, or parts thereof, in which the ceramic or metal powder material used to form the article comprises a radiolucent material and a radiopaque material.
- radiolucent particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having an average particulate size of no more than 40 microns
- radiopaque particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having an average particulate size of no more than 40 microns, and
- Articles, especially surgical implements comprising an article composed of a sintered mixture of radiolucent and radiopaque powders as described herein, and medical devices comprising such implements are other aspects of the invention.
- a further aspect of the invention is a surgical method in which a surgical implement as described herein is carried via a catheter to a remote site within the body and used in performing a surgical procedure, wherein the article of the invention is observed fluoroscopically during at least a portion of the time it is in the body.
- FIG. 2 is an orthagonal view of a ceramic tip for an RF-PMR catheter fashioned in accordance with the present invention.
- FIG. 1 is a perspective view of a single jaw of a biopsy forceps fashioned in accordance with the present invention.
- FIG. 3 is a perspective fragmentary view of a stent fashioned in accordance with the present invention.
- the invention is preferably practiced to prepare articles which are, or are components of surgical implements adapted for delivery and operation at a remote site within the body on a catheter.
- the subject article is composed of a mixture of at least two inorganic ceramic or metallurgic materials, one of which is radiolucent, (i.e. invisible or only weakly visible fluoroscopically), and the second of which is radiopaque (readily visible fluoroscopically).
- Particulate materials suitable for the radiolucent inorganic material making up the component (i) of the moldable compositions include:
- ceramic materials such as alumina, aluminum nitride, silica, silicon, silicon carbide, silicon nitride, sialon, zirconia, zirconium nitride, zirconium carbide, zirconium boride, titania, titanium nitride, titanium carbide, barium titanate, titanium boride, boron nitride, boron carbide, magnesium oxide, calcium oxide, and the like, and combinations thereof; and
- metallurigic materials including metals, and mixtures or alloys thereof such as stainless steel, iron, nickel, titanium, nitinol, and metallic oxides which can be converted to metals when sintered in a reducing environment, and combinations thereof.
- radiolucent ceramic and metallurgic materials may also be employed as the component (i).
- Preferred radiolucent materials include alumina, zirconia, and 17-4 PH, MP35N, 316 LVM, and 304V stainless steels.
- Particulate materials suitable for the inorganic radiopaque material making up the component (ii) of the moldable compositions include:
- ceramic materials such as tungsten carbide, and tungsten boride, and
- metallurgic materials such as platinum, tantalum, iridium, tungsten, rhenium gold and alloys of such metals.
- radiopaque ceramic and metallurgic materials may also be employed as the component (ii).
- Preferred radiopaque materials include platinium, tungsten, rhenium and tantalum.
- the morphology of the inorganic particulate materials (i) and (ii) is not critical but is preferably approximately spherical.
- the particle sizes of the materials will both be within the range suitable for forming sintered articles, suitably an average of about 40 micrometers (microns) or less, more preferably an average of from about 0.5 to about 10 micrometers in diameter.
- the ratio of the radiolucent and radiopaque materials may vary widely, depending on the desired structural properties and radiopacity of the finished article.
- the radiopaque material (ii) will constitute at least 2% and no more than about 75% by volume of the total volume of the components (i) and (ii). More typically, structural and/or cost factors will favor the radiolucent component, so that the radiopaque component will constitute no more than 50% by volume and preferably no more than about 35% by volume of the two.
- the fluoroscopic visibility of the implement may not be adequately enhanced. Consequently it will generally be desirable to employ at least 5% and often 10% or more of the radiopaque component, based on the total volume of these two components.
- the radiopaque material have a melting point which is not substantially lower than the radiolucent material so that fluidization of the radiopaque material does not occur before the radiolucent material reaches, sintering temperature. More preferably the radiopaque material has a melting point which is about the same or is even higher than that of the radiolucent material.
- the third component of the composition is a binder material (iii).
- a binder material Any material suitable as a binder material for CIM or MIM processes may be used.
- Exemplary materials include polyolefins, such as polyethylene and propylene; olefin copolymers such as ethylene vinyl acetate copolymers; poly(meth)acrylates including polymethyl methacrylate, polybutyl methacrylate and the like; polystyrene and other styrene group resins; polyvinyl chloride; polyamides; polyesters; polyethers; polyacetals; various types of wax, including paraffin; and the like.
- Exemplary binders are described in EP-A-0 444 475, EP-A-0 446 708 and EP-A-0 444 475, incorporated herein by reference.
- the binding agents are employed in conventional amounts, generally from about 2% to about 30% by weight of the injection moldable composition. More preferably the binder will be employed in an amount of from about 4 to about 15% by weight of the composition. Generally lower amounts of binder will be preferred to minimize shrinkage during sintering. However, with very complex shapes, if the shrinkage is carefully controlled to give good reproducibility and avoid shape distortion, high shrinkage may be advantage in allowing larger molds to be used to produce the preform.
- additives known in the art may be added in conventional to the moldable composition.
- additives include plasticizing agents, lubricating agents, antioxidants, degreasing promotion agents, and surfactants.
- composition of the inorganic powders (i) and (ii), the binder (iii) and any other additives are suitably blended in a kneading machine above the melting point of the binder and the kneaded product pelletized before use.
- any other conventional mixing technique may be used and/or the blended mixture may be used without pelletization.
- the composition produced as described above is injection molded into a compacted preform.
- the dimensions of the mold are set taking into account the shrinkage that will occur from the later sintering step.
- Typical molding conditions will provide the composition to the mold at a temperature above the melting point of the binder, typically from about 130-200° C. and at injection pressure of from about 30,000 to as high as 200,000 kPa.
- the mold temperature suitably will be below that of the composition, and below the glass transition temperature of the binder, typically from about 5° C. to about 50° C.
- the mold may be at a higher temperature when the composition is injected and then subsequently cooled.
- the preform produced in this step is then removed from the mold.
- a binder extraction process may be performed on the preform.
- a binder extraction process may be performed on the preform.
- the binder In forming sintered parts it is not always necessary to remove the binder as it may vaporize/decompose during sintering. However, better dimensional stability results are often obtained if the binder is removed before the preform is sintered.
- Known binder removal methods include solvent extraction, thermal decomposition/vaporization at a temperature below the sintering temperature, and chemical decompositon, for instance decomposition of polyacetal resins by exposure to an acidic gas at elevated temperature. Combinations of such removal methods may also be employed. Suitable conditions for such binder extractions are known in the art.
- the preform is heated under conditions suitable for sintering the inorganic particles of the components (i) and (ii).
- Typical conditions will be a temperature of from about 400° C. to about 1700° C. for about 10 to about 30 hours, although higher temperatures and longer or shorter times may be suitable for some articles.
- the sintering step will be conducted in a non-oxidizing atmosphere, for example, in argon gas or other inactive gases, under a vacuum or reduced pressure conditions.
- hydrogen will be provided to accomplish a reduction of such oxide to the metal during sintering.
- a reduction process adaptable to the present invention is described in U.S. Pat. No. 6,080,808, incorporated herein by reference.
- surface hardness or other desirable properties may be imparted to the implement by providing an atmosphere containing one or more gas(es) containing least one of C, O or N during a portion of the sintering time.
- gases may be selected from air, O 2 , CO 2 , CO, N 2 , methane, acetylene, propane and mixtures thereof.
- the formed article may be subjected to any necessary finishing steps. For example, lubricity coatings may be applied, finishing machining may be performed, and/or surface processing may be performed such as shot blasting, honing, grinding, etching, wet plating, vacuum evaporation, ion plating, spattering, CVD, and the like.
- various material properties of the inventive implement can be controlled or set. Examples of such properties include the composition of the surface layer, the pore diameter, and the number of pores.
- the invention permits the radiographic contrast range of the article to be tailored to permit ready visualization, without creating an X-ray artifact which masks the surrounding vessel and tissue. This is especially important in surgical techniques practiced via catheters, since, once the article has been delivered to the site of treatment it is often necessary to visualize surrounding tissue in order to successfully perform a procedure. Still further, in the case of an implement, such as a stent, which is left in the body as a result of the procedure, it is important to monitor the tissue condition through the stent subsequent to placement to verify vessel patentcy. For this reason, the implement needs to be bright enough during X-ray fluoroscopy to be seen using an X-ray intensity which allows visualization of the surrounding tissue, but dim enough to be seen through.
- FIG. 1 a single jaw 10 of a two-jaw biopsy forceps which may be mounted on a catheter and transported via the vascular system from a remote location to a diseased or transplanted heart and at that location deployed and operated to grab a tissue sample. The forceps is then removed from the body and the tissue sample retrieved for inspection.
- Such forceps jaws T-Rex® are now conventionally made by machining a blank of a medical grade stainless steel.
- the delivery and removal of the forceps, as well as its operation at the heart site, may be more easily monitored than if the forceps jaws are made only from machined stainless steel.
- FIG. 2 shows a perspective view of a ceramic tip 20 for a PMR catheter, conventionally made of alumina by a CIM process.
- the tip serves an an insulator and mechanical stop for an RF electrode array used to treat myocardial infarction.
- the delivery and removal of the catheter may be easily monitored without the necessity of providing radiopaque marker bands or the like.
- the manufacturing process is simplified and components presenting potential bonding issues are eliminated.
- FIG. 3 shows a porous drug delivery stent 30 of the type described in U.S. Pat. No. 5,972,027, made from sintered stainless steel powder.
- a porous drug delivery stent 30 of the type described in U.S. Pat. No. 5,972,027, made from sintered stainless steel powder.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials For Medical Uses (AREA)
- Electrotherapy Devices (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Powder Metallurgy (AREA)
Abstract
X-ray imageable articles, for instance surgical implements or parts therefore which are used in minimally invasive surgical procedures, may be prepared by a process including the steps of:
(a) preparing a mixture composition comprising:
i) radiolucent particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having a particulate size of no more than 40 microns,
ii) radiopaque particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having a particulate size of no more than 40 microns, and
(iii) at least one polymeric binder material;
(b) injection molding the mixture composition into a preform;
(c) optionally removing the binder material from the preform; and
(d) sintering the preform.
Description
- This invention relates to medical devices which are inserted into the body and located by X-ray imaging.
- Various types of minimally invasive surgical techniques have been developed in recent years in which catheters or similar devices are used to convey a operative implement through a body passage, including such passages as the blood vessels, gastrointestinal tract, urethral and urethral tracts, bronchial and esophageal tracts, to a specific location where the implement is operatively employed or delivered. Catheters are used to perform balloon angioplasty, to deliver and lodge stent devices, to deliver drugs, to abrade or volatilize lesions, to remove temporary, misplaced or dislodged stents, and the like. For such activities, X-ray imaging is often used to follow the catheter or the operative implement as it traverses the body channel and/or to monitor the actual employment or deployment of the implement.
- For materials which are transparent to X-ray, or are only weakly radiopaque, it has been conventional to provide radiopaque marker bands, coatings or laminates of more intensely radiopaque materials on the devices or implements in order to achieve the necessary contrast for a readily observable image.
- A number of the implements, used or delivered by such techniques, or parts thereof may be made of metal or ceramic materials. Traditionally such implements are, or are made up of, small complex machined parts. Stents are an example of such an implement which is typically made by machining metal.
- A technique which is known for manufacturing metal and ceramic parts utilizes injection molding and sintering of composite formulations. This technique, designated “CIM” for ceramic articles and “MIM” for metal articles utilizes formulations which are mixtures of a resinous binder material and a very fine powder of the respective ceramic or metal material, which is injection molded to produce a desired shaped article, the molded article typically being somewhat larger than the desired size. The binder is then typically removed by extraction, heating, or both, leaving a shaped structure of the powder material. This structure is sintered to form the final article, typically shrinking by a reproducible amount.
- Similar products can be prepared from combining ceramic materials with metallurgic materials to form what is known as a “cermet.”
- A porous stent formed by a powdered metal sintering process is disclosed in U.S. Pat. No. 5,972,027, incorporated herein by reference in its entirety. A perfulsion tip for an ablation catheter is described in U.S. 6,017,338, incorporated herein by reference in its entirety.
- The present invention is directed to articles which can be made using a CIM or MIM process, preferably articles which are, or are part, of surgical implement structures such as catheters, forcepts, stents, perfusion heads, electrodes, and the like used in minimally invasive surgical procedures and. The invention also relates to CIM or MIM processes for preparing such implements, or parts thereof, in which the ceramic or metal powder material used to form the article comprises a radiolucent material and a radiopaque material.
- In a first aspect of the present invention there is provided a method for preparing an X-ray imageable article comprising:
- (a) preparing a mixture composition comprising:
- i) radiolucent particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having an average particulate size of no more than 40 microns,
- ii) radiopaque particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having an average particulate size of no more than 40 microns, and
- (iii) at least one polymeric binder material;
- (b) injection molding the mixture composition into a preform;
- (c) optionally removing the binder material from the preform; and
- (d) sintering the preform.
- Articles, especially surgical implements comprising an article composed of a sintered mixture of radiolucent and radiopaque powders as described herein, and medical devices comprising such implements are other aspects of the invention.
- A further aspect of the invention is a surgical method in which a surgical implement as described herein is carried via a catheter to a remote site within the body and used in performing a surgical procedure, wherein the article of the invention is observed fluoroscopically during at least a portion of the time it is in the body.
- Still further aspects of the invention are described in the detailed description below and in the claims.
- FIG. 2 is an orthagonal view of a ceramic tip for an RF-PMR catheter fashioned in accordance with the present invention.
- FIG. 1 is a perspective view of a single jaw of a biopsy forceps fashioned in accordance with the present invention.
- FIG. 3 is a perspective fragmentary view of a stent fashioned in accordance with the present invention.
- As noted above the invention is preferably practiced to prepare articles which are, or are components of surgical implements adapted for delivery and operation at a remote site within the body on a catheter.
- According to the invention the subject article is composed of a mixture of at least two inorganic ceramic or metallurgic materials, one of which is radiolucent, (i.e. invisible or only weakly visible fluoroscopically), and the second of which is radiopaque (readily visible fluoroscopically).
- Particulate materials suitable for the radiolucent inorganic material making up the component (i) of the moldable compositions include:
- ceramic materials such as alumina, aluminum nitride, silica, silicon, silicon carbide, silicon nitride, sialon, zirconia, zirconium nitride, zirconium carbide, zirconium boride, titania, titanium nitride, titanium carbide, barium titanate, titanium boride, boron nitride, boron carbide, magnesium oxide, calcium oxide, and the like, and combinations thereof; and
- metallurigic materials including metals, and mixtures or alloys thereof such as stainless steel, iron, nickel, titanium, nitinol, and metallic oxides which can be converted to metals when sintered in a reducing environment, and combinations thereof.
- Combinations of such inorganic radiolucent ceramic and metallurgic materials may also be employed as the component (i). Preferred radiolucent materials include alumina, zirconia, and 17-4 PH, MP35N, 316 LVM, and 304V stainless steels.
- Particulate materials suitable for the inorganic radiopaque material making up the component (ii) of the moldable compositions include:
- ceramic materials such as tungsten carbide, and tungsten boride, and
- metallurgic materials such as platinum, tantalum, iridium, tungsten, rhenium gold and alloys of such metals.
- Combinations of such inorganic radiopaque ceramic and metallurgic materials may also be employed as the component (ii). Preferred radiopaque materials include platinium, tungsten, rhenium and tantalum.
- The morphology of the inorganic particulate materials (i) and (ii) is not critical but is preferably approximately spherical. The particle sizes of the materials will both be within the range suitable for forming sintered articles, suitably an average of about 40 micrometers (microns) or less, more preferably an average of from about 0.5 to about 10 micrometers in diameter.
- The ratio of the radiolucent and radiopaque materials may vary widely, depending on the desired structural properties and radiopacity of the finished article. Generally the radiopaque material (ii) will constitute at least 2% and no more than about 75% by volume of the total volume of the components (i) and (ii). More typically, structural and/or cost factors will favor the radiolucent component, so that the radiopaque component will constitute no more than 50% by volume and preferably no more than about 35% by volume of the two. On the other hand, if too little of the radiopaque component is employed the fluoroscopic visibility of the implement may not be adequately enhanced. Consequently it will generally be desirable to employ at least 5% and often 10% or more of the radiopaque component, based on the total volume of these two components.
- Also, it is generally preferred that the radiopaque material have a melting point which is not substantially lower than the radiolucent material so that fluidization of the radiopaque material does not occur before the radiolucent material reaches, sintering temperature. More preferably the radiopaque material has a melting point which is about the same or is even higher than that of the radiolucent material.
- The third component of the composition is a binder material (iii). Any material suitable as a binder material for CIM or MIM processes may be used. Exemplary materials include polyolefins, such as polyethylene and propylene; olefin copolymers such as ethylene vinyl acetate copolymers; poly(meth)acrylates including polymethyl methacrylate, polybutyl methacrylate and the like; polystyrene and other styrene group resins; polyvinyl chloride; polyamides; polyesters; polyethers; polyacetals; various types of wax, including paraffin; and the like. Exemplary binders are described in EP-A-0 444 475, EP-A-0 446 708 and EP-A-0 444 475, incorporated herein by reference.
- The binding agents are employed in conventional amounts, generally from about 2% to about 30% by weight of the injection moldable composition. More preferably the binder will be employed in an amount of from about 4 to about 15% by weight of the composition. Generally lower amounts of binder will be preferred to minimize shrinkage during sintering. However, with very complex shapes, if the shrinkage is carefully controlled to give good reproducibility and avoid shape distortion, high shrinkage may be advantage in allowing larger molds to be used to produce the preform.
- In addition to the three components described above, various additives known in the art may be added in conventional to the moldable composition. Examples of such additives include plasticizing agents, lubricating agents, antioxidants, degreasing promotion agents, and surfactants.
- The composition of the inorganic powders (i) and (ii), the binder (iii) and any other additives are suitably blended in a kneading machine above the melting point of the binder and the kneaded product pelletized before use. Alternatively any other conventional mixing technique may be used and/or the blended mixture may be used without pelletization.
- In the second step of the inventive process the composition produced as described above is injection molded into a compacted preform. The dimensions of the mold are set taking into account the shrinkage that will occur from the later sintering step. Typical molding conditions will provide the composition to the mold at a temperature above the melting point of the binder, typically from about 130-200° C. and at injection pressure of from about 30,000 to as high as 200,000 kPa. The mold temperature suitably will be below that of the composition, and below the glass transition temperature of the binder, typically from about 5° C. to about 50° C. Alternatively the mold may be at a higher temperature when the composition is injected and then subsequently cooled. The preform produced in this step is then removed from the mold.
- After the preform is removed from the mold a binder extraction process may be performed on the preform. In forming sintered parts it is not always necessary to remove the binder as it may vaporize/decompose during sintering. However, better dimensional stability results are often obtained if the binder is removed before the preform is sintered. Known binder removal methods include solvent extraction, thermal decomposition/vaporization at a temperature below the sintering temperature, and chemical decompositon, for instance decomposition of polyacetal resins by exposure to an acidic gas at elevated temperature. Combinations of such removal methods may also be employed. Suitable conditions for such binder extractions are known in the art.
- Next, the preform, either as obtained directly from the mold or after binder extraction is heated under conditions suitable for sintering the inorganic particles of the components (i) and (ii). Typical conditions will be a temperature of from about 400° C. to about 1700° C. for about 10 to about 30 hours, although higher temperatures and longer or shorter times may be suitable for some articles. Typically the sintering step will be conducted in a non-oxidizing atmosphere, for example, in argon gas or other inactive gases, under a vacuum or reduced pressure conditions. In some instances, for instance where the metallurgic material is a metal oxide, hydrogen will be provided to accomplish a reduction of such oxide to the metal during sintering. A reduction process adaptable to the present invention is described in U.S. Pat. No. 6,080,808, incorporated herein by reference.
- In some cases surface hardness or other desirable properties may be imparted to the implement by providing an atmosphere containing one or more gas(es) containing least one of C, O or N during a portion of the sintering time. Such gases may be selected from air, O 2, CO2, CO, N2, methane, acetylene, propane and mixtures thereof.
- After sintering, the formed article may be subjected to any necessary finishing steps. For example, lubricity coatings may be applied, finishing machining may be performed, and/or surface processing may be performed such as shot blasting, honing, grinding, etching, wet plating, vacuum evaporation, ion plating, spattering, CVD, and the like.
- The powder injection molding method described above allows complicated shapes to be formed monolithically with a tailored radiopacity in a simple and repeatable high production rate process.
- Through adjustment of types of binding agents, added amounts, binder extraction conditions, and sintering conditions, various material properties of the inventive implement can be controlled or set. Examples of such properties include the composition of the surface layer, the pore diameter, and the number of pores.
- The invention permits the radiographic contrast range of the article to be tailored to permit ready visualization, without creating an X-ray artifact which masks the surrounding vessel and tissue. This is especially important in surgical techniques practiced via catheters, since, once the article has been delivered to the site of treatment it is often necessary to visualize surrounding tissue in order to successfully perform a procedure. Still further, in the case of an implement, such as a stent, which is left in the body as a result of the procedure, it is important to monitor the tissue condition through the stent subsequent to placement to verify vessel patentcy. For this reason, the implement needs to be bright enough during X-ray fluoroscopy to be seen using an X-ray intensity which allows visualization of the surrounding tissue, but dim enough to be seen through.
- Referring now to the Figures, there is shown in FIG. 1 a
single jaw 10 of a two-jaw biopsy forceps which may be mounted on a catheter and transported via the vascular system from a remote location to a diseased or transplanted heart and at that location deployed and operated to grab a tissue sample. The forceps is then removed from the body and the tissue sample retrieved for inspection. Such forceps jaws (T-Rex®) are now conventionally made by machining a blank of a medical grade stainless steel. When made in accordance with the present invention from a mixture of powders of a medical grade stainless steel and a radiopaque metal such as platinum or tungsten, the delivery and removal of the forceps, as well as its operation at the heart site, may be more easily monitored than if the forceps jaws are made only from machined stainless steel. - FIG. 2 shows a perspective view of a
ceramic tip 20 for a PMR catheter, conventionally made of alumina by a CIM process. The tip serves an an insulator and mechanical stop for an RF electrode array used to treat myocardial infarction. When made in accordance with the present invention from a mixture of powders of a medical grade alumina and tungsten or rhenium, the delivery and removal of the catheter may be easily monitored without the necessity of providing radiopaque marker bands or the like. Thus the manufacturing process is simplified and components presenting potential bonding issues are eliminated. - FIG. 3 shows a porous
drug delivery stent 30 of the type described in U.S. Pat. No. 5,972,027, made from sintered stainless steel powder. When made in accordance with the present invention from a mixture of powders of a medical grade stainless steel and a radiopaque metal such as tantalum, platinum or tungsten, the delivery of the stent, and its functioning to maintain vessel patency may be more easily monitored than if the stent is made only from sintered stainless steel powder. - While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
- The above examples and disclosure are intended to be illustrative and not exhaustive. These examples and description will suggest many variations and alternatives to one of ordinary skill in this art. All these alternatives and variations are intended to be included within the scope of the attached claims. Those familiar with the art may recognize other equivalents to the specific embodiments described herein which equivalents are also intended to be encompassed by the claims attached hereto. Further, the particular features presented in the dependent claims below can be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims.
Claims (25)
1. A method for preparing an X-ray imageable article comprising:
(a) preparing a mixture composition comprising:
i) radiolucent particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having an average particulate size of no more than 40 microns,
ii) radiopaque particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having an average particulate size of no more than 40 microns, and
(iii) at least one polymeric binder material;
(b) injection molding the mixture composition into a preform;
(c) optionally removing the binder material from the preform; and
(d) sintering the preform.
2. A method as in claim 1 wherein said article is a surgical implement or component thereof, said implement adapted to be disposed on a catheter and conveyed thereon a remote site within the body and operated at such site to perform a surgical procedure.
3. A method as in claim 1 wherein said radiolucent material is selected from the group consisting of alumina, aluminum nitride, silica, silicon, silicon carbide, silicon nitride, sialon, zirconia, zirconium nitride, zirconium carbide, zirconium boride, titania, titanium nitride, titanium carbide, barium titanate, titanium boride, boron nitride, boron carbide, magnesium oxide, calcium oxide, stainless steel, iron, nickel, titanium, nitinol, and metallic oxides which can be converted to metals when sintered in a reducing environment, and combinations thereof.
4. A method as in claim 1 wherein said radiopaque material is selected from the group consisting of tungsten carbide, tungsten boride, the metals platinum, tantalum, iridium, tungsten, rhenium and gold, alloys of said metals, and combinations thereof.
5. A method as in claim 1 wherein the radiopaque material (ii) constitutes at least 2% and no more than about 75% by volume of the total volume of the components (i) and (ii).
6. A method as in claim 1 wherein the radiolucent material is selected from the group consisting of alumina, zirconia and stainless steel and the radiopaque material is selected from the group consisting of platinum, tungsten, rhenium and tantalum, and the radiopaque material constitutes from about 10 to about 50% by volume of the total volume of the components (i) and (ii).
7. A method as in claim 1 wherein the binder component (iii) is selected from the group consisting of polyolefins; olefin copolymers such as ethylene vinyl acetate copolymers; poly(meth)acrylates; styrene group resins; polyvinyl chloride; polyamides; polyesters; polyethers; polyacetals; and waxes.
8. A method as in claim 1 wherein the binder component (iii) is employed in said mixture composition in an amount of from about 2% to about 30% by weight thereof.
9. A method as in claim 1 wherein the binder removal step c) is preformed.
10. An article comprising a sintered mixture of at least two inorganic powder materials at least one of which is a radiolucent and at least one of which is radiopaque.
11. A medical device comprising an article as in claim 10 .
12. A medical device as in claim 11 wherein said device comprises a catheter and said article is a surgical implement which can be carried on the catheter to a remote site within the body.
13. A medical device as in claim 12 wherein said radiolucent material is selected from the group consisting of alumina, aluminum nitride, silica, silicon, silicon carbide, silicon nitride, sialon, zirconia, zirconium nitride, zirconium carbide, zirconium boride, titania, titanium nitride, titanium carbide, barium titanate, titanium boride, boron nitride, boron carbide, magnesium oxide, calcium oxide, stainless steel, iron, nickel, titanium, nitinol, and metallic oxides which can be converted to metals when sintered in a reducing environment, and combinations thereof.
14. A medical device as in claim 12 wherein said radiopaque material is selected from the group consisting of tungsten carbide, tungsten boride, the metals platinum, tantalum, iridium, tungsten, rhenium and gold, alloys of said metals, and combinations thereof.
15. A medical device as in claim 12 wherein the radiopaque material constitutes at least 2% and no more than about 75% by volume of the total volume of the radiolucent and the radiopaque materials.
16. A medical device as in claim 12 wherein the radiolucent material is selected from the group consisting of alumina, zirconia and stainless steel and the radiopaque material is selected from the group consisting of platinum, tungsten, rhenium and tantalum, and the radiopaque material constitutes from about 10 to about 50% by volume of the total volume of the radiolucent and the radiopaque materials.
17. A composition useful for preparing radiopaque components of a medical device structure, the composition comprising a mixture of
i) radiolucent particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having an average particulate size of no more than 40 microns,
ii) radiopaque particulate material selected from ceramic materials, metallurgic materials, and combinations thereof and having an average particulate size of no more than 40 microns, and
(iii) at least one polymeric binder material.
18. A composition as in claim 17 wherein:
the radiolucent material is selected from the group consisting of alumina, aluminum nitride, silica, silicon, silicon carbide, silicon nitride, sialon, zirconia, zirconium nitride, zirconium carbide, zirconium boride, titania, titanium nitride, titanium carbide, barium titanate, titanium boride, boron nitride, boron carbide, magnesium oxide, calcium oxide, stainless steel, iron, nickel, titanium, nitinol, and metallic oxides which can be converted to metals when sintered in a reducing environment, and combinations thereof;
the radiopaque material is selected from the group consisting of tungsten carbide, tungsten boride, the metals platinum, tantalum, iridium, tungsten, rhenium and gold, alloys of said metals, and combinations thereof;
the radiopaque material constitutes at least 2% and no more than about 75% by volume of the total volume of the radiolucent and the radiopaque materials; and. the binder material is present in said composition in an amount of from about 2% to about 30% by weight thereof.
19. A composition as in claim 17 wherein the radiolucent material is selected from the group consisting of alumina, zirconia and stainless steel and the radiopaque material is selected from the group consisting of platinum, tungsten, rhenium and tantalum, and the radiopaque material constitutes from about 10 to about 50% by volume of the total volume of the radiolucent and the radiopaque materials.
20. A composition as in claim 17 wherein the average particle sizes of the radiolucent and radiopaque materials are from about 0.5 to about 10 micrometers.
21. A composition as in claim 17 wherein the radiopaque material has a melting point which is greater than or equal to the melting point of the radiolucent material.
22. A surgical method comprising conveying a surgical implement via a catheter to a remote site within the body, using said implement to perform a surgical procedure at said site and observing the implement fluoroscopically during at least a portion of the time it is in the body, wherein the implement comprises an article as in claim 10 .
23. A surgical method as in claim 22 wherein the radiolucent and the radiopaque powder materials are present in relative amounts which renders the article bright enough during X-ray fluoroscopy to be seen using an X-ray intensity which allows visualization of the surrounding tissue, but dim enough to be seen through.
24. A method as in claim 2 wherein the radiolucent and the radiopaque powder materials are present in relative amounts which renders the article, when in the body, bright enough during X-ray fluoroscopy to be seen using an X-ray intensity which allows visualization of the surrounding tissue, but dim enough to be seen through.
25 A medical device as in claim 12 wherein the radiolucent and the radiopaque powder materials are present in relative amounts which renders the article, when in the body, bright enough during X-ray fluoroscopy to be seen using an X-ray intensity which allows visualization of the surrounding tissue, but dim enough to be seen through.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/701,223 US20040092818A1 (en) | 2000-11-15 | 2003-11-04 | Radiopaque surgical implement |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/713,064 US6641776B1 (en) | 2000-11-15 | 2000-11-15 | Method for preparing radiopaque surgical implement |
| US10/701,223 US20040092818A1 (en) | 2000-11-15 | 2003-11-04 | Radiopaque surgical implement |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/713,064 Continuation US6641776B1 (en) | 2000-11-15 | 2000-11-15 | Method for preparing radiopaque surgical implement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040092818A1 true US20040092818A1 (en) | 2004-05-13 |
Family
ID=24864603
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/713,064 Expired - Lifetime US6641776B1 (en) | 2000-11-15 | 2000-11-15 | Method for preparing radiopaque surgical implement |
| US10/701,223 Abandoned US20040092818A1 (en) | 2000-11-15 | 2003-11-04 | Radiopaque surgical implement |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/713,064 Expired - Lifetime US6641776B1 (en) | 2000-11-15 | 2000-11-15 | Method for preparing radiopaque surgical implement |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6641776B1 (en) |
| EP (1) | EP1341566B1 (en) |
| JP (1) | JP2004513709A (en) |
| AU (2) | AU2002232519B2 (en) |
| CA (1) | CA2427767A1 (en) |
| DE (1) | DE60108524T2 (en) |
| WO (1) | WO2002040077A2 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050021129A1 (en) * | 2000-12-28 | 2005-01-27 | Pelton Brian Lee | Thermoelastic and superelastic Ni-Ti-W alloy |
| US20070131318A1 (en) * | 2005-12-12 | 2007-06-14 | Accellent, Inc. | Medical alloys with a non-alloyed dispersion and methods of making same |
| US20070154466A1 (en) * | 2005-12-30 | 2007-07-05 | Jan Weber | Internal medical devices containing peroxide-converting catalysts |
| US20070178005A1 (en) * | 2006-01-27 | 2007-08-02 | Accellent, Inc. | Metal injection molded article with a radiopaque dispersion and methods of making same |
| US20100151216A1 (en) * | 2007-01-08 | 2010-06-17 | High Impact Technology, L.L.C. | Stratified panel structure possessing interleaved, thin-high-density, thick-low-density core-structure stack arrangement |
| US20100178194A1 (en) * | 2009-01-12 | 2010-07-15 | Accellent, Inc. | Powder extrusion of shaped sections |
| WO2011136810A1 (en) * | 2010-04-30 | 2011-11-03 | Accellent, Inc. | Pressure forming of metal and ceramic powders |
| US20140088419A1 (en) * | 2011-05-09 | 2014-03-27 | Ingemar Näslund | Positioning marker |
| US8721643B2 (en) | 2005-08-23 | 2014-05-13 | Smith & Nephew, Inc. | Telemetric orthopaedic implant |
| US9492210B2 (en) | 2008-10-15 | 2016-11-15 | Smith & Nephew, Inc. | Composite internal fixators |
| US9849216B2 (en) | 2006-03-03 | 2017-12-26 | Smith & Nephew, Inc. | Systems and methods for delivering a medicament |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6926733B2 (en) * | 2001-08-02 | 2005-08-09 | Boston Scientific Scimed, Inc. | Method for enhancing sheet or tubing metal stent radiopacity |
| US7065394B2 (en) * | 2001-12-12 | 2006-06-20 | Medtronic, Inc | Guide catheter |
| US6725901B1 (en) * | 2002-12-27 | 2004-04-27 | Advanced Cardiovascular Systems, Inc. | Methods of manufacture of fully consolidated or porous medical devices |
| US7399296B2 (en) * | 2003-02-26 | 2008-07-15 | Medtronic Vascular, Inc. | Catheter having highly radiopaque embedded segment |
| DE10317241A1 (en) | 2003-04-10 | 2004-10-28 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | stent |
| US20050055080A1 (en) * | 2003-09-05 | 2005-03-10 | Naim Istephanous | Modulated stents and methods of making the stents |
| US20050064223A1 (en) | 2003-09-22 | 2005-03-24 | Bavaro Vincent Peter | Polymeric marker with high radiopacity |
| US20050255317A1 (en) | 2003-09-22 | 2005-11-17 | Advanced Cardiovascular Systems, Inc. | Polymeric marker with high radiopacity for use in medical devices |
| US7641983B2 (en) * | 2005-04-04 | 2010-01-05 | Boston Scientific Scimed, Inc. | Medical devices including composites |
| EP1945171B1 (en) * | 2005-11-03 | 2011-12-21 | Zhilong Xu | A medical device's manufacture and usage in alternative medicine for rehabilitation treatment of chronic diseases |
| US8267695B2 (en) | 2006-04-17 | 2012-09-18 | Kabushiki Kaisha Shofu | Tooth for dental arch model and method for producing the same |
| DE102006038238A1 (en) * | 2006-08-07 | 2008-02-14 | Biotronik Vi Patent Ag | X-ray marker for medical implants made of a biocorrodible metallic material |
| EP2114480B1 (en) * | 2006-12-28 | 2016-01-06 | Boston Scientific Limited | Medical devices and methods of making the same |
| AT504975B1 (en) * | 2007-02-19 | 2013-12-15 | Arc Austrian Res Centers Gmbh | GRID PART OF METAL AND METHOD FOR PRODUCING A GRID PART |
| US20090054760A1 (en) * | 2007-08-24 | 2009-02-26 | Burke Harry B | Catheter for Enhanced Image Location Detection |
| EP2149414A1 (en) | 2008-07-30 | 2010-02-03 | Nederlandse Centrale Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek TNO | Method of manufacturing a porous magnesium, or magnesium alloy, biomedical implant or medical appliance. |
| WO2010059408A2 (en) * | 2008-11-23 | 2010-05-27 | Medtronic, Inc. | Medical devices with encapsulated visibility particles |
| WO2010059409A2 (en) * | 2008-11-23 | 2010-05-27 | Medtronic, Inc. | Medical devices with dual modality visible segments |
| US9050396B2 (en) | 2009-02-27 | 2015-06-09 | Halifax Biomedical Inc. | Device and method for bone imaging |
| US20120316430A1 (en) * | 2011-06-10 | 2012-12-13 | Cibor, Inc. | Radiolucent surgical instruments |
| WO2015035282A1 (en) | 2013-09-06 | 2015-03-12 | Polyone Corporation | Radiopaque, optically translucent thermoplastic compounds |
| US10231777B2 (en) | 2014-08-26 | 2019-03-19 | Covidien Lp | Methods of manufacturing jaw members of an end-effector assembly for a surgical instrument |
| DE102016110294A1 (en) * | 2016-06-03 | 2017-12-07 | Olympus Winter & Ibe Gmbh | Surgical jaw instrument |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321042A (en) * | 1976-03-16 | 1982-03-23 | Hans Scheicher | Ceramic dental implant |
| US4927866A (en) * | 1988-02-29 | 1990-05-22 | Espe Stiftung & Co. Produktions- Und Vertriebs Kg | Shapable material and shaped articles obtainable therefrom |
| US5062798A (en) * | 1988-04-27 | 1991-11-05 | Ngk Spark Plug Co., Ltd. | SiC based artificial dental implant |
| US5344456A (en) * | 1989-06-06 | 1994-09-06 | Tdk Corporation | Materials for living hard tissue replacements |
| US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
| US5503771A (en) * | 1991-05-14 | 1996-04-02 | Washington Technology Center | Process for susupension of ceramic or metal particles using biologically produced polymers |
| US5679470A (en) * | 1993-01-19 | 1997-10-21 | Schneider (Usa) Inc. | Process for manufacturing clad composite stent |
| US5725570A (en) * | 1992-03-31 | 1998-03-10 | Boston Scientific Corporation | Tubular medical endoprostheses |
| US5733326A (en) * | 1996-05-28 | 1998-03-31 | Cordis Corporation | Composite material endoprosthesis |
| US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
| US5989476A (en) * | 1998-06-12 | 1999-11-23 | 3D Systems, Inc. | Process of making a molded refractory article |
| US6017338A (en) * | 1993-12-21 | 2000-01-25 | Angeion Corporation | Fluid cooled and perfused tip for a catheter |
| US6027528A (en) * | 1996-05-28 | 2000-02-22 | Cordis Corporation | Composite material endoprosthesis |
| US6080808A (en) * | 1997-01-07 | 2000-06-27 | Basf Aktiengesellschaft | Injection-molding compositions containing metal oxides for the production of metal moldings |
| US6087024A (en) * | 1996-12-17 | 2000-07-11 | Whinnery; Leroy Louis | Method for forming porous sintered bodies with controlled pore structure |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149734A (en) | 1989-10-20 | 1992-09-22 | General Electric Company | Highly filled thermoplastic polyester molding compositions |
| DE59101468D1 (en) | 1990-02-21 | 1994-06-01 | Basf Ag | Thermoplastic compositions for the production of ceramic moldings. |
| DE4007345A1 (en) | 1990-03-08 | 1991-09-12 | Basf Ag | THERMOPLASTIC MEASURES FOR THE PRODUCTION OF METALLIC MOLDED BODIES |
| US5088927A (en) | 1990-06-18 | 1992-02-18 | Lee Howard G | Radio opaque plastics and process of making |
| US6399018B1 (en) | 1998-04-17 | 2002-06-04 | The Penn State Research Foundation | Powdered material rapid production tooling method and objects produced therefrom |
-
2000
- 2000-11-15 US US09/713,064 patent/US6641776B1/en not_active Expired - Lifetime
-
2001
- 2001-11-13 DE DE60108524T patent/DE60108524T2/en not_active Expired - Lifetime
- 2001-11-13 WO PCT/US2001/047120 patent/WO2002040077A2/en not_active Ceased
- 2001-11-13 AU AU2002232519A patent/AU2002232519B2/en not_active Ceased
- 2001-11-13 JP JP2002542447A patent/JP2004513709A/en active Pending
- 2001-11-13 AU AU3251902A patent/AU3251902A/en active Pending
- 2001-11-13 EP EP01992045A patent/EP1341566B1/en not_active Expired - Lifetime
- 2001-11-13 CA CA002427767A patent/CA2427767A1/en not_active Abandoned
-
2003
- 2003-11-04 US US10/701,223 patent/US20040092818A1/en not_active Abandoned
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321042A (en) * | 1976-03-16 | 1982-03-23 | Hans Scheicher | Ceramic dental implant |
| US4927866A (en) * | 1988-02-29 | 1990-05-22 | Espe Stiftung & Co. Produktions- Und Vertriebs Kg | Shapable material and shaped articles obtainable therefrom |
| US4927866B1 (en) * | 1988-02-29 | 1992-02-04 | Espe Stiftung | |
| US5062798A (en) * | 1988-04-27 | 1991-11-05 | Ngk Spark Plug Co., Ltd. | SiC based artificial dental implant |
| US5344456A (en) * | 1989-06-06 | 1994-09-06 | Tdk Corporation | Materials for living hard tissue replacements |
| US5503771A (en) * | 1991-05-14 | 1996-04-02 | Washington Technology Center | Process for susupension of ceramic or metal particles using biologically produced polymers |
| US5725570A (en) * | 1992-03-31 | 1998-03-10 | Boston Scientific Corporation | Tubular medical endoprostheses |
| US5679470A (en) * | 1993-01-19 | 1997-10-21 | Schneider (Usa) Inc. | Process for manufacturing clad composite stent |
| US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
| US6017338A (en) * | 1993-12-21 | 2000-01-25 | Angeion Corporation | Fluid cooled and perfused tip for a catheter |
| US5733326A (en) * | 1996-05-28 | 1998-03-31 | Cordis Corporation | Composite material endoprosthesis |
| US6027528A (en) * | 1996-05-28 | 2000-02-22 | Cordis Corporation | Composite material endoprosthesis |
| US6087024A (en) * | 1996-12-17 | 2000-07-11 | Whinnery; Leroy Louis | Method for forming porous sintered bodies with controlled pore structure |
| US6080808A (en) * | 1997-01-07 | 2000-06-27 | Basf Aktiengesellschaft | Injection-molding compositions containing metal oxides for the production of metal moldings |
| US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
| US5989476A (en) * | 1998-06-12 | 1999-11-23 | 3D Systems, Inc. | Process of making a molded refractory article |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658760B2 (en) | 2000-12-28 | 2010-02-09 | Abbott Cardiovascular Systems Inc. | Thermoelastic and superelastic Ni-Ti-W alloy |
| US20050021129A1 (en) * | 2000-12-28 | 2005-01-27 | Pelton Brian Lee | Thermoelastic and superelastic Ni-Ti-W alloy |
| US8382819B2 (en) | 2000-12-28 | 2013-02-26 | Abbot Cardiovascular Systems Inc. | Thermoelastic and superelastic Ni-Ti-W alloy |
| US8974517B2 (en) | 2000-12-28 | 2015-03-10 | Abbott Cardiovascular Systems Inc. | Thermoelastic and superelastic NI-TI-W alloy |
| US8702790B2 (en) | 2000-12-28 | 2014-04-22 | Abbott Cardiovascular Systems Inc. | Thermoelastic and superelastic Ni—Ti—W alloy |
| US8721643B2 (en) | 2005-08-23 | 2014-05-13 | Smith & Nephew, Inc. | Telemetric orthopaedic implant |
| US20070131318A1 (en) * | 2005-12-12 | 2007-06-14 | Accellent, Inc. | Medical alloys with a non-alloyed dispersion and methods of making same |
| US20070131317A1 (en) * | 2005-12-12 | 2007-06-14 | Accellent | Nickel-titanium alloy with a non-alloyed dispersion and methods of making same |
| US20070154466A1 (en) * | 2005-12-30 | 2007-07-05 | Jan Weber | Internal medical devices containing peroxide-converting catalysts |
| US20070178005A1 (en) * | 2006-01-27 | 2007-08-02 | Accellent, Inc. | Metal injection molded article with a radiopaque dispersion and methods of making same |
| US9849216B2 (en) | 2006-03-03 | 2017-12-26 | Smith & Nephew, Inc. | Systems and methods for delivering a medicament |
| US20100151216A1 (en) * | 2007-01-08 | 2010-06-17 | High Impact Technology, L.L.C. | Stratified panel structure possessing interleaved, thin-high-density, thick-low-density core-structure stack arrangement |
| US9492210B2 (en) | 2008-10-15 | 2016-11-15 | Smith & Nephew, Inc. | Composite internal fixators |
| US10357292B2 (en) | 2008-10-15 | 2019-07-23 | Smith & Nephew, Inc. | Composite internal fixators |
| US11096726B2 (en) | 2008-10-15 | 2021-08-24 | Smith & Nephew, Inc. | Composite internal fixators |
| US20100178194A1 (en) * | 2009-01-12 | 2010-07-15 | Accellent, Inc. | Powder extrusion of shaped sections |
| WO2011136810A1 (en) * | 2010-04-30 | 2011-11-03 | Accellent, Inc. | Pressure forming of metal and ceramic powders |
| US9789543B2 (en) | 2010-04-30 | 2017-10-17 | Accellent Inc. | Pressure forming of metal and ceramic powders |
| CN103764060A (en) * | 2011-05-09 | 2014-04-30 | 英格马尔·内斯隆德 | positioning mark |
| US20140088419A1 (en) * | 2011-05-09 | 2014-03-27 | Ingemar Näslund | Positioning marker |
| US9579160B2 (en) * | 2011-05-09 | 2017-02-28 | Ingemar Näslund | Positioning marker |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1341566B1 (en) | 2005-01-19 |
| EP1341566A2 (en) | 2003-09-10 |
| WO2002040077A2 (en) | 2002-05-23 |
| JP2004513709A (en) | 2004-05-13 |
| AU3251902A (en) | 2002-05-27 |
| AU2002232519B2 (en) | 2007-03-01 |
| CA2427767A1 (en) | 2003-05-23 |
| WO2002040077A3 (en) | 2003-01-03 |
| DE60108524D1 (en) | 2005-02-24 |
| US6641776B1 (en) | 2003-11-04 |
| DE60108524T2 (en) | 2005-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6641776B1 (en) | Method for preparing radiopaque surgical implement | |
| AU2002232519A1 (en) | Radiopaque surgical implement | |
| EP1866006B1 (en) | Medical devices including composites | |
| EP2114480B1 (en) | Medical devices and methods of making the same | |
| CN108526469B (en) | Composite for metal powder injection molding, formed body, sintered body, and production method | |
| AU2011244998B2 (en) | Method for the manufacture of a shaped body as well as green compact | |
| US20080069854A1 (en) | Medical devices and methods of making and using | |
| US20080124373A1 (en) | Lumen - supporting devices and methods of making and using | |
| EP1813367A2 (en) | Metal injection molded article with a radiopaque dispersion and methods of making same | |
| WO2006096263A2 (en) | Process for forming an improved metal alloy stent | |
| Wu et al. | Surface characteristics, mechanical properties, and cytocompatibility of oxygen plasma‐implanted porous nickel titanium shape memory alloy | |
| JP2018138688A (en) | Compound for metal powder injection molding, metal powder compact, method for producing sintered compact, and sintered compact | |
| JP2002526389A (en) | Bioactive composite material and method for producing the same | |
| JP7583248B2 (en) | Method for manufacturing composite particles, composite powder, and composite member using the composite powder | |
| WO2009070133A1 (en) | Process for forming an improved metal alloy stent | |
| DE102018105489A1 (en) | Composite materials based on tungsten carbide with precious metal binders and use and process for their preparation | |
| EP2124844A1 (en) | Endoprostheses including metal matrix composite structures | |
| JPH0698903A (en) | Production of bioimplant material | |
| JPH05222402A (en) | Method for manufacturing tungsten heavy alloy products | |
| JPH04323307A (en) | Production of tungsten heavy metal product | |
| Lucas et al. | Orthopaedic alloys |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |